Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | FPR3 | P25089 | 1/20 | 0.30 |
| ▸ | TSPO | P30536 | 1/20 | 0.30 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12534734 | 0.90 | CRHR1 (0.32) | LRRK2FPR3TSPOCRHR1TMEM97 | |
| SCHEMBL12534820 | 0.84 | CRHR1 (0.33) | FPR3TSPOCRHR1TMEM97 | |
| SCHEMBL12534724 | 0.84 | CRHR1 (0.39) | LRRK2FPR3TSPOCRHR1TMEM97 | |
| SCHEMBL12534745 | 0.84 | CRHR1 (0.41) | LRRK2CRHR1MAP2K7 | |
| SCHEMBL1638401 | 0.84 | KDM4E (0.32) | FPR3TSPOCRHR1TMEM97MAP2K7 | |
| SCHEMBL12534784 | 0.84 | MAP2K7 (0.31) | FPR3TSPOCRHR1TMEM97MAP2K7 | |
| SCHEMBL12534825 | 0.82 | CRHR1 (0.33) | FPR3TSPOCRHR1TMEM97 | |
| SCHEMBL1638289 | 0.79 | MAP2K7 (0.42) | FPR3TSPOCRHR1TMEM97MAP2K7 | |
| SCHEMBL12534767 | 0.78 | CRHR1 (0.35) | FPR3TSPOCRHR1TMEM97 | |
| SCHEMBL1636919 | 0.77 | JAK2 (0.37) | FPR3TSPOCRHR1TMEM97MAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455511-B2 | Pyrrolopyridine derivatives substituted with cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-02 | — | — | US | disclosed |
| US-7932259-B2 | Pyrrolo[2,3-d]pyrimidine derivatives substituted with a cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20080287397-A1 | Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group | TASHO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287397-A1 | Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group | HRH2, HRH4, CRHR1 | LRRK2 614/4885FPR3 157/4885TSPO 2034/4885 |
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | HRH2, HRH4, CRHR1 | LRRK2 702/4885FPR3 171/4885TSPO 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.